MedGenesis Therapeutix, a biotechnology company, has received a grant from the Deutsche Parkinson Vereinigung e.V. for the Phase II development of glial cell line derived neurotrophic factor (GDNF).

MedGenesis chairman and CEO Dr. Erich Mohr said the Deutsche Parkinson Vereinigung joined the alliance in support of GDNF program in Parkinson's disease.

"GDNF has the potential to become the first disease-modifying treatment in Parkinson's disease and could significantly change the quality of life of the affected patients," Dr. Mohr added.

MedGenesis Therapeutix is focused on the development of definitive treatments for serious conditions such as Parkinson's disease, epilepsy, brain cancer and other severely debilitating diseases of the central nervous system.

The Deutsche Parkinson Vereinigung e.V. managing director Friedrich-Wilhelm Mehrhoff said, "On behalf of our association and all those patients suffering from Parkinson's disease, we are pleased to have the opportunity to support this program that may have a distinct impact on the disease and gives reason for hope to many patients."